X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cuprior (trientine tetrahydrochloride) is a copper chelator which eliminates absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. It is approved for the treatment of Wilson disease.
Lead Product(s): Trientine Tetrahydrochloride
Therapeutic Area: Genetic Disease Product Name: Cuprior
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Cuvrior (trientine hydrochloride) is a copper chelator that forms a complex with absorbed copper and then gets eliminated through urinary excretion. It is available in US for the treatment of stable Wilson disease who are de-coppered and tolerant to penicillamine.
Lead Product(s): Trientine Tetrahydrochloride
Therapeutic Area: Genetic Disease Product Name: Cuvrior
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Using this NCC measurement Cuvrior (trientine tetrahydrochloride) was determined to be non-inferior to penicillamine at primary endpoint of study (24 weeks), with same observation at end of extension phase of study in patients receiving maintenance penicillamine therapy.
Lead Product(s): Trientine Tetrahydrochloride
Therapeutic Area: Genetic Disease Product Name: Cuvrior
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2022
Details:
Cuvrior™ (trientine tetrahydrochloride) is an oral trientine formulation. In the U.S., trientine tetrahydrochloride has been granted Orphan Drug Designation for the treatment of Wilson’s disease.
Lead Product(s): Trientine Tetrahydrochloride
Therapeutic Area: Genetic Disease Product Name: Cuvrior
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Orphalan recently completed a global phase III trial, CHELATE, which met its primary efficacy endpoint by demonstrating that Cuvrior, a new salt of trientine (trientine tetrahydrochloride) was non-inferior to penicillamine as measured by non-ceruloplasmin copper.
Lead Product(s): Trientine Tetrahydrochloride
Therapeutic Area: Genetic Disease Product Name: Cuvrior
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
